Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | GGT1 | P19440 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.32 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.31 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | GRN | P28799 | 1/20 | 0.30 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3378525 | 0.80 | GABRR1 (0.40) | GABRR1LMNAGGT1FOLH1RIMKLA | |
| SCHEMBL31419895 | 0.80 | GABRR1 (0.40) | GABRR1LMNAGGT1FOLH1RIMKLA | |
| SCHEMBL2192135 | 0.78 | GGT1 (0.47) | GABRR1LMNAGGT1FOLH1RIMKLA | |
| SCHEMBL13145343 | 0.78 | — | — | |
| SCHEMBL5974497 | 0.77 | SMN1; SMN2 (0.50) | GABRR1LMNAFOLH1RIMKLANAALAD2 | |
| SCHEMBL468724 | 0.77 | SMN1; SMN2 (0.50) | GABRR1LMNAFOLH1RIMKLANAALAD2 | |
| SCHEMBL29713557 | 0.77 | GABRR1 (0.42) | GABRR1LMNAGGT1FOLH1RIMKLA | |
| SCHEMBL5974504 | 0.77 | SMN1; SMN2 (0.50) | GABRR1LMNAFOLH1RIMKLANAALAD2 | |
| SCHEMBL4753597 | 0.76 | GGH (0.42) | GABRR1LMNAGGT1FOLH1 | |
| SCHEMBL3378500 | 0.75 | FOLH1 (0.49) | GABRR1LMNACYP1A2TSHRGGT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240091121-A1 | PHOSPHONATES AND N-HALAMINES COMPOSITIONS FOR TARTAR REMOVAL | O.Y.M. INNOVATION LTD. (IL) | 2024-03-21 | — | — | US | disclosed |
| EP-4274539-A2 | PHOSPHONATES AND N-HALAMINES COMPOSITIONS FOR TARTAR REMOVAL | O.Y.M. Innovation Ltd. (IL) | 2023-11-15 | — | — | EP | disclosed |
| WO-2022149126-A2 | PHOSPHONATES AND N-HALAMINES COMPOSITIONS FOR TARTAR REMOVAL | O.Y.M. INNOVATION LTD. (IL) | 2022-07-14 | — | — | WO | disclosed |
| WO-2010017405-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | HELLER ADAM (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091121-A1 | PHOSPHONATES AND N-HALAMINES COMPOSITIONS FOR TARTAR REMOVAL | PHOSPHO1, PHPT1, PTMS | GABRR1 3803/4885LMNA 1066/4885CYP1A2 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.